Milestone Pharmaceuticals Inc. (MIST) Q3 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, ladies and gentlemen, and welcome to the Milestone Pharmaceuticals Investor and Analyst Webcast. As a reminder, this call is being recorded. I would now like to turn the call over to Joseph Aliveto, President and CEO of Milestone Pharmaceuticals. Mr. Aliveto? Thank you, Keith. Good morning, everyone, and thank you for joining us today to review our new, recently presented, and published results from Rivera, our Phase II study evaluating atripamil and in patients with atrial fibrillation with rapid ventricular rate. As a reminder, a slide webcast accompanying today's remarks is available on our website at milestonepharma.com. During today's call, we will be making forward-looking statements, so we'll direct you to our SEC filings for a full disclosure of our risk factors. For today's call, We are honored to be joined by two leading cardiac electrophysiologists and atrial fibrillation experts. And I'd like to welcome Dr. John Kam, British Heart Foundation Emeritus Professor of Clinical Cardiology, the Cardiology Clinic Academic Group, Molecular and Clinical Sciences Research Institute at St. George's University of London. And Dr. Sean Picorni, Director of Arrhythmia Core Laboratory, Duke Clinical Research Institute, and Assistant Professor of Medicine, Duke University School of Medicine. Thank you both for joining us for today's call. Joining me for prepared remarks from our milestone team is Dr. David Beruccia, our Chief Medical Officer. In addition, we will be joined for the Q&A portion of the call by Amit Hesija, our Chief Financial Officer, and Lorenz Muller, our Chief Commercial Officer. I'll now provide a brief overview of the agenda for today's call. Dr. Kam will provide an overview of the positive results from our Rivera Phase II study evaluating atri...